Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Sold by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. trimmed its position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 55.6% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 306,744 shares of the company’s stock after selling 384,322 shares during the period. D. E. Shaw & Co. Inc. owned 0.45% of Amylyx Pharmaceuticals worth $1,159,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of AMLX. JPMorgan Chase & Co. lifted its holdings in Amylyx Pharmaceuticals by 144.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 140,559 shares of the company’s stock worth $455,000 after buying an additional 83,048 shares during the last quarter. American Century Companies Inc. lifted its stake in Amylyx Pharmaceuticals by 181.8% during the fourth quarter. American Century Companies Inc. now owns 59,310 shares of the company’s stock worth $224,000 after purchasing an additional 38,261 shares during the last quarter. Dimensional Fund Advisors LP acquired a new position in Amylyx Pharmaceuticals in the fourth quarter worth $205,000. Wellington Management Group LLP bought a new stake in Amylyx Pharmaceuticals during the fourth quarter valued at $793,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in Amylyx Pharmaceuticals during the fourth quarter valued at $56,000. 95.84% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Amylyx Pharmaceuticals news, insider Camille L. Bedrosian sold 12,425 shares of the firm’s stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $3.47, for a total value of $43,114.75. Following the completion of the transaction, the insider now directly owns 194,375 shares in the company, valued at $674,481.25. This trade represents a 6.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO James M. Frates sold 10,896 shares of the business’s stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $3.47, for a total transaction of $37,809.12. Following the transaction, the chief financial officer now owns 290,988 shares in the company, valued at $1,009,728.36. This represents a 3.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 48,980 shares of company stock worth $168,627. Insiders own 11.70% of the company’s stock.

Amylyx Pharmaceuticals Price Performance

Shares of AMLX stock opened at $5.31 on Friday. The firm has a market cap of $473.34 million, a price-to-earnings ratio of -1.39 and a beta of -0.60. Amylyx Pharmaceuticals, Inc. has a one year low of $1.58 and a one year high of $7.27. The stock’s fifty day simple moving average is $4.31 and its 200 day simple moving average is $4.20.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.03. On average, research analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have weighed in on AMLX. Mizuho increased their target price on Amylyx Pharmaceuticals from $7.00 to $8.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 14th. Leerink Partners upgraded shares of Amylyx Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $4.00 to $10.00 in a research note on Wednesday, May 7th. HC Wainwright upped their price target on Amylyx Pharmaceuticals from $12.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday, May 9th. Finally, Leerink Partnrs raised Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 6th. One analyst has rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Amylyx Pharmaceuticals has an average rating of “Buy” and an average price target of $9.83.

Amylyx Pharmaceuticals Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.